ClinicalTrials.gg
RecruitingNCT03049072REGI-MA-002015Updated Mar 23, 2026

Ion Therapy Patient Registry

An observational study in Ion Beam Radiation Therapy for Tumor Patients, sponsored by EBG MedAustron GmbH. Recruiting at 1 site in Austria. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by EBG MedAustron GmbH · Observational

How we know

From the registry’s dates

  • Started Dec 2016; still recruiting 9 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,800
Sex
All
01

Study summary

The purpose of the study is the prospective and standardized data collection of patients treated with ion therapy at MedAustron.

Read the detailed description

During and up to 10 years after radiation therapy data regarding tumor control and treatment response as well as acute and late toxicities will be collected at regular time intervals. Additionally quality of life and sociodemographic status will be assessed in all study patients and neurocognitive assessment will be performed in patients undergoing ion radiation of the brain.

02

Conditions studied

  • Ion Beam Radiation Therapy for Tumor Patients
03

In context

Lead sponsor

EBG MedAustron GmbH is the lead sponsor of 6 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients treated with ion beam therapy at MedAustron

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with tumor disease treated with ion beam therapy at MedAustron
  • Signed form

Exclusion criteria

Exclusion Criteria:

  • Comorbidities endangering treatment delivery or study compliance
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,800 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes

Groups and cohorts

  • Ion beam therapy

    All patients treated with ion beam therapy at MedAustron who consent to the participation in the registry.

    Radiation: Protons and Carbon Ions

Interventions

  • RadiationProtons and Carbon Ions
06

What researchers measure

Primary outcomes

  1. Therapy response

    Therapy Response according to RECIST Version 1.1

    Time frame: 10 years

  2. Overall survival

    Time frame: 10 years

  3. Progression-free survival

    Time frame: 10 years

  4. Local progression-free survival

    Time frame: 10 years

  5. Cause-specific survival

    Time frame: 10 years

  6. Toxicity according to NCI CTCAE

    Acute/late toxicity according to CTCAEv4.03, June 14,2010

    Time frame: 10 years

Secondary outcomes

  1. EORTC-QLQ-C30

    Patient-reported quality of life

    Time frame: Through study completion, at 3, 5, and 10 years

  2. EORTC-QLQ-BN20

    Patient-reported quality of life for brain cancer patients

    Time frame: Through study completion, at 3, 5, and 10 years

  3. EORTC-QLQ-PR25

    Patient-reported quality of life for prostate cancer patients

    Time frame: Through study completion, at 3, 5, and 10 years

  4. Neurocognitive test battery

    Change in cognition from baseline to endpoint as measured by standardized subtests of test battery

    Time frame: Through study completion, at 3, 5, and 10 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2016 (actual). Primary completion is estimated for Dec 2031, 180 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2017
First posted
Feb 9, 2017
StartActual
Dec 2016
Primary completionEst.
Dec 2031
CompletionEst.
Dec 2036
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03049072
Lead sponsor
EBG MedAustron GmbH
Responsible party
Sponsor
First posted
Feb 9, 2017
Start date
Dec 2016
Primary completion
Dec 2031 (estimated)
Completion
Dec 2036 (estimated)
Last update
Mar 23, 2026

Study contacts

Yvonne Goy, MD
Contact
yvonne.goy@medaustron.at
+43 2622 26 100 ext. 407
Piero Fossati, MD MSc
Contact
piero.fossati@medaustron.at
+43 2622 26 100 ext. 408
Yvonne Goy, MD
principal investigator · EBG MedAustron GmbH
Piero Fossati, MD MSc
principal investigator · EBG MedAustron GmbH
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion